IBDEI1PP ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,29078,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29078,1,3,0)
 ;;=3^Fetomaternal placental transfusion syndrome, third trimester
 ;;^UTILITY(U,$J,358.3,29078,1,4,0)
 ;;=4^O43.013
 ;;^UTILITY(U,$J,358.3,29078,2)
 ;;=^5017391
 ;;^UTILITY(U,$J,358.3,29079,0)
 ;;=O36.0110^^115^1455^43
 ;;^UTILITY(U,$J,358.3,29079,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29079,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, first trimester, unsp
 ;;^UTILITY(U,$J,358.3,29079,1,4,0)
 ;;=4^O36.0110
 ;;^UTILITY(U,$J,358.3,29079,2)
 ;;=^5016842
 ;;^UTILITY(U,$J,358.3,29080,0)
 ;;=O36.0111^^115^1455^44
 ;;^UTILITY(U,$J,358.3,29080,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29080,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, first tri, fetus 1
 ;;^UTILITY(U,$J,358.3,29080,1,4,0)
 ;;=4^O36.0111
 ;;^UTILITY(U,$J,358.3,29080,2)
 ;;=^5016843
 ;;^UTILITY(U,$J,358.3,29081,0)
 ;;=O36.0112^^115^1455^45
 ;;^UTILITY(U,$J,358.3,29081,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29081,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, first tri, fetus 2
 ;;^UTILITY(U,$J,358.3,29081,1,4,0)
 ;;=4^O36.0112
 ;;^UTILITY(U,$J,358.3,29081,2)
 ;;=^5016844
 ;;^UTILITY(U,$J,358.3,29082,0)
 ;;=O36.0113^^115^1455^46
 ;;^UTILITY(U,$J,358.3,29082,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29082,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, first tri, fetus 3
 ;;^UTILITY(U,$J,358.3,29082,1,4,0)
 ;;=4^O36.0113
 ;;^UTILITY(U,$J,358.3,29082,2)
 ;;=^5016845
 ;;^UTILITY(U,$J,358.3,29083,0)
 ;;=O36.0114^^115^1455^47
 ;;^UTILITY(U,$J,358.3,29083,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29083,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, first tri, fetus 4
 ;;^UTILITY(U,$J,358.3,29083,1,4,0)
 ;;=4^O36.0114
 ;;^UTILITY(U,$J,358.3,29083,2)
 ;;=^5016846
 ;;^UTILITY(U,$J,358.3,29084,0)
 ;;=O36.0115^^115^1455^48
 ;;^UTILITY(U,$J,358.3,29084,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29084,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, first tri, fetus 5
 ;;^UTILITY(U,$J,358.3,29084,1,4,0)
 ;;=4^O36.0115
 ;;^UTILITY(U,$J,358.3,29084,2)
 ;;=^5016847
 ;;^UTILITY(U,$J,358.3,29085,0)
 ;;=O36.0120^^115^1455^49
 ;;^UTILITY(U,$J,358.3,29085,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29085,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, second trimester, unsp
 ;;^UTILITY(U,$J,358.3,29085,1,4,0)
 ;;=4^O36.0120
 ;;^UTILITY(U,$J,358.3,29085,2)
 ;;=^5016849
 ;;^UTILITY(U,$J,358.3,29086,0)
 ;;=O36.0121^^115^1455^50
 ;;^UTILITY(U,$J,358.3,29086,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29086,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, second tri, fetus 1
 ;;^UTILITY(U,$J,358.3,29086,1,4,0)
 ;;=4^O36.0121
 ;;^UTILITY(U,$J,358.3,29086,2)
 ;;=^5016850
 ;;^UTILITY(U,$J,358.3,29087,0)
 ;;=O36.0122^^115^1455^51
 ;;^UTILITY(U,$J,358.3,29087,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29087,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, second tri, fetus 2
 ;;^UTILITY(U,$J,358.3,29087,1,4,0)
 ;;=4^O36.0122
 ;;^UTILITY(U,$J,358.3,29087,2)
 ;;=^5016851
 ;;^UTILITY(U,$J,358.3,29088,0)
 ;;=O36.0123^^115^1455^52
 ;;^UTILITY(U,$J,358.3,29088,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29088,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, second tri, fetus 3
 ;;^UTILITY(U,$J,358.3,29088,1,4,0)
 ;;=4^O36.0123
 ;;^UTILITY(U,$J,358.3,29088,2)
 ;;=^5016852
 ;;^UTILITY(U,$J,358.3,29089,0)
 ;;=O36.0124^^115^1455^53
 ;;^UTILITY(U,$J,358.3,29089,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29089,1,3,0)
 ;;=3^Maternal care for anti-D antibodies, second tri, fetus 4
 ;;^UTILITY(U,$J,358.3,29089,1,4,0)
 ;;=4^O36.0124
